Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Belite Bio, Inc

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Participate in the BTIG Ophthalmology Day
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008)
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022
From Belite Bio, Inc
Via GlobeNewswire
Tickers BLTE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.